Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

Company Pauses OV101 Program Based On NEPTUNE Results

 
• By Alaric DeArment

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

nerve cells, concept for neurodegenerative and neurological disease
Ovid shifts focus after Phase III Angelman syndrome study disappoints. • Source: Shutterstock

More from Neurological

More from Therapy Areas